My Companies
Notification
Account
Log Out
Login
Biocon launched Yesafili, an interchangeable biosimilar to Eylea 2 mg, in the U.S., targeting a $5.89 billion reference product market. It is indicated for wet AMD and other eye conditions.
Biocon Launches Yesafili Aflibercept Biosimilar Commercially In United States
Mylan Sells Entire 5.64% Biocon Stake In Open Market Deal